Review of the converging pathophysiology of T2DM, MASLD, and cardiovascular disease as an interconnected clinical triad, with emphasis on insulin resistance, systemic inflammation, and endothelial dysfunction as shared mechanistic drivers, and the role of incretin therapies including tirzepatide in addressing multiple components simultaneously. Contextualizes the multi-indication benefit profile of tirzepatide. Provides clinicians managing the common T2DM-MASLD-CVD triad with a mechanistic rationale for preferring tirzepatide as a multi-target therapy—demonstrating how dual GIP/GLP-1 agonism addresses the core pathophysiological drivers of all three converging conditions.
Abstract
The coexistence of type 2 diabetes (T2D), metabolic dysfunction-associated steatotic liver disease (MASLD), and cardiovascular disease (CVD) defines a clinical profile that is frequently observed in clinical practice. In addition to being highly prevalent, patients with this triad of diseases experience accelerated vascular aging and poor prognosis. Insulin resistance remains the common symptom; however, the systemic impact of this extends far beyond glucose handling, shaping inflammation, oxidative stress, and endothelial dysfunction. In this review, we highlight how these intertwined conditions challenge current diagnostic frameworks and therapeutic approaches. Moreover, we discuss under-recognized aspects, such as the contribution of gut-derived metabolites and adipose dysfunction, which often remain neglected in routine care despite strong mechanistic evidence. We also summarize the potential of noninvasive tools, biomarkers, and cardioprotective agents, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and tirzepatide. While promising, these agents still face gaps in translation to everyday hepatology and cardiology clinics. Our message is that prevention and care should not be compartmentalized. Instead, an integrated, patient-centered approach, with early screening and multidisciplinary management, is needed to address this complex interplay. Moreover, recognizing the shared pathways of T2D, MASLD, and CVD may help clinicians anticipate potential complications and design more effective and sustainable strategies for long-term outcomes.